All Articles

Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment

Cancer-associated fibroblast cell surface markers as potential biomarkers or therapeutic targets in lung cancer

Research progress on the role and mechanism of circular RNA in drug resistance of head and neck squamous cell carcinoma

The role of circRNAs and miRNAs in drug resistance and targeted therapy responses in breast cancer

The uniqueness of ABCB5 as a full transporter ABCB5FL and a half-transporter-like ABCB5β

Targeting NETosis: nature's alarm system in cancer progression

Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy

Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review

Inhibition of glutaminolysis alone and in combination with HDAC inhibitor has anti-myeloma therapeutic effects

Recent advanced lipid-based nanomedicines for overcoming cancer resistance

The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer

Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer

Validation of single nucleotide polymorphisms potentially related to R-CHOP resistance in diffuse large B-cell lymphoma patients

ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies

Chemosensitizing effect of pentoxifylline in sensitive and multidrug-resistant non-small cell lung cancer cells

Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them

Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers

Isocucurbitacin B inhibits glioma growth through PI3K/AKT pathways and increases glioma sensitivity to TMZ by inhibiting hsa-mir-1286a